Subscribe to RSS
DOI: 10.1055/s-2004-814280
Aminoglykosid- und Cisplatin-Ototoxizität: von der Grundlagenforschung zur Klinik
Aminoglycoside- and Cisplatin-ototoxicity: From Basic Science to ClinicsPublication History
Eingegangen: 3. September 2003
Angenommen: 2. Januar 2004
Publication Date:
14 May 2004 (online)
![](https://www.thieme-connect.de/media/lro/200405/lookinside/thumbnails/10.1055-s-2004-814280-1.jpg)
Zusammenfassung
Gentamicin und Cisplatin sind trotz der bekannten Oto- und Nephrotoxizität klinisch häufig verwendete Pharmaka. Bezüglich der Pathomechanismen der Nebenwirkungen auf das Innenohr wie auch der Protektionsmöglichkeiten finden sich Ähnlichkeiten, aber auch einige Unterschiede. In dieser Übersichtsarbeit wird die Bedeutung reaktiver Sauerstoffspezies, des antioxidativen Abwehrsystems, des zellulären Eisens und Kalziums sowie des Stickstoffmonoxids und der Neurotrophine für die Gentamicin- und Cisplatin-Ototoxizität beschrieben. Weiterhin wird auf Zelltodmechanismen sowie auf die Bedeutung der Mitochondrien für zellschädigende Prozesse näher eingegangen.
Abstract
Gentamicin and cisplatin are clinically widely used pharmacological agents which may induce irreversible hearing loss as a side effect. Concerning the pathomechanisms of ototoxicity as well as preventive strategies there are similarities but also some differences. In this review we focus on the role of reactive oxygen species, the antioxidant system, cellular iron and calcium as well as nitric oxide and neurotrophins on gentamicin- and cisplatin-ototoxicity. Furthermore we deal with apoptotic and necrotic cell death as well as the role of mitochondria in these cell injury processes.
Schlüsselwörter
Gentamicin - Cisplatin - Eisen - reaktive Sauerstoffspezies - Mitochondrien
Key words
Gentamicin - cisplatin - iron - reactive oxygen species - mitochondria
Literatur
- 1 Dulon D, Zajic G, Aran J M, Schacht J. Aminoglycoside antibiotics impair calcium entry but not vulnerability and motility in isolated cochlear outer hair cells. J Neurosci Res. 1989; 24 338-346
- 2 Kroese A BA, van den Bercken J. Effects of ototoxic antibiotics on sensory cells functioning. Hear Res. 1982; 6 183-197
- 3 Kroese A BA, Das A, Hudspeth A J. Blockage of the transduction channels of hair cells in the bull frog’s sacculus by aminoglycoside antibiotics. Hear Res. 1989; 37 203-218
- 4 Crann S A, Huang M Y, McLaren J D, Schacht J. Formation of a toxic metabolite from gentamicin by a hepatic cytosolic fraction. Biochem Pharmacol. 1992; 43 1835-1839
- 5 Priuska E M, Clark-Baldwin K, Pecocaro V L, Schacht J. NMR studies of iron-gentamicin complexes and the implications for aminoglycoside toxicity. Inorganica Chimica Acta. 1998; 273 85-91
- 6 Priuska E M, Schacht J. Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex. Biochem Pharmacol. 1995; 50 1749-1752
- 7 Sha S H, Schacht J. Formation of reactive oxygen species following bioactivation of gentamicin. Free Rad Biol Med. 1999a; 26 341-347
- 8 Sha S H, Schacht J. Stimulation of free radical formation by aminoglycoside antibiotics. Hear Res. 1999b; 128 112-118
- 9 Halliwell B, Gutteridge J MC. Free Radicals in Biology and Medicine. New York; Oxford University Press 1999
- 10 Petrat F, de Groot H, Sustmann R, Rauen U. The chelatable iron pool in living cells. A methodically defined quantity. Biol Chem. 2002; 383 489-502
- 11 Clerici W J, Hensley K, DiMartino D L, Butterfield D A. Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants. Hear Res. 1996; 98 116-124
- 12 Hirose K, Hockenberry D N, Rubel E W. Reactive oxygen species in chick hair cells after gentamicin exposure in vitro. Hear Res. 1997; 104 1-14
- 13 Schacht J. Isolation of aminoglycoside receptor from guinea pig inner ear tissues and kidney. Arch Otorhinolaryngol. 1979; 224 129-134
- 14 Williams S E, Zenner H P, Schacht J. Three molecular steps of aminoglycoside ototoxicity demonstrated in outer hair cells. Hear Res. 1987; 30 11-18
- 15 Forge A, Zajic G, Davies S, Weiner N, Schacht J. Gentamicin alters membrane structure as shown by freeze fracture of liposomes. Hear Res. 1989; 37 129-140
- 16 Song B B, Anderson D J, Schacht J. Protection from gentamicin ototoxicity by iron chelators in guinea pig in vivo. J Pharmacol Exp Ther. 1997; 282 369-377
- 17 Walker P D, Shah S V. Evidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in rats. J Clin Invest. 1988; 81 334-341
- 18 Dehne N, Lautermann J, Petrat F, Rauen U, de Groot H. Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals. Toxicol Appl Pharmacol. 2001; 174 27-34
- 19 Dehne N, Rauen U, de Groot H, Lautermann J. Involvement of the mitochondrial permeability transition in gentamicin ototoxicty. Hear Res. 2002; 169 47-55
- 20 Sha S H, Schacht J. Salicylate attenuates gentamicin-induced ototoxicity. Lab Invest. 1999c; 79 807-813
- 21 Dinis T C, Maderia V M, Almeida L M. Action of phenolic derivatives (acetaminophen, salicylate, and 5-aminosalicylate) as inhibitors of membrane lipid peroxidation and as peroxyl radical scavengers. Arch Biochem Biophys. 1994; 315 161-169
- 22 Huang W, Chen Y, Zha D, Qiu J, Wang J, Sha S, Schacht J. Prevention of aminoglycoside-induced hearing loss by aspirin: preliminary data from a clinical study. Abstr Assoc Res Otolaryngol. 2002; 25 262
- 23 Prazma J, Garrison H G, Williford S K, Ferguson S D, Fischer J, Drake A, Klingler L E. Alteration of aminoglycoside antibiotic ototoxicity, effect of semistarvation. Ann Otol Rhinol Laryngol. 1983; 92 178-182
- 24 Garetz S L, Altschuler R A, Schacht J. Attenuation of gentamicin ototoxicity by glutathione in the guinea pig in vivo. Hear Res. 1994; 77 81-87
- 25 Lautermann J, McLaren J, Schacht J. Glutathione protection against gentamicin ototoxicity depends on nutritional status. Hear Res. 1995a; 86 15-24
- 26 Nakashimi T, Tanabe T, Yanagita N, Wakai K, Ohno Y. Risk factors for sudden deafness: a case control study. Auris Nasus Larynx. 1997; 24 265-270
- 27 Takumida M, Anniko M. Direct evidence of nitric oxide production in the guinea pig organ of Corti. Acta Otolaryngol. 2001a; 121 342-345
- 28 Takumida M, Anniko M. Nitric oxide in guinea pig vestibular sensory cells following gentamicin exposure in vitro. Acta Otolaryngol. 2001b; 121 346-350
- 29 Mc Fadden S, Ding D, Salvemini D, Salvi R J. M40403, a superoxide dismutase mimetic, protects cochlear hair cells from gentamicin, but not cisplatin toxicity. Tox Appl Pharmacol. 2003; 186 46-54
- 30 Takumida M, Popa R, Anniko M. Free radicals in the guinea pig inner ear following gentamicin exposure. ORL J Otorhinolaryngol Relat Spec. 1999; 61 63-70
- 31 Jiang H, Sha SH, Schacht J. Kanamycin increases reactive oxygen species and apoptosis in the mouse cochlea. Abs Assoc Res Otolaryngol. 25; abstract 133 2002
- 32 Pullan L M, Stumpo R J, Powel R J, Paschetto K A, Britt M. Neomycin is an agonist at a polyamine site on the N-methyl-D-aspartate receptor. J Neurochem. 1992; 59 2087-2093
- 33 Basile A S, Huang J M, Xie C, Webster D, Berlin C, Skolnick P. N-methyl-D-aspartate antagonists limit aminoglycoside-induced hearing loss. Nat Med. 1996; 2 1338-1343
- 34 Sha SH, Schacht J. Are aminoglycoside antibiotics excitotoxic?. NeuroReport. 1998; 9 3893-3895
- 35 Duan M, Agerman K, Ernfors P, Canlon B. Complementary roles of neurotrophin 3 and N-methyl-D-aspartate antagonist in the protection of noise and aminoglycoside-induced ototoxicity. PNAS. 2000; 97 7597-7602
- 36 Kroemer G, Reed J C. Mitochondrial control of cell death. Nat Med. 2000; 6 513-519
- 37 Fischel-Ghodsian N. Mitochondrial deafness. Ear Hear. 2003; 24 303-313
- 38 Kupka S, Toth T, Wrobel M, Zeissler U, Szyfter W, Szyfter K, Niedzielska G, Bal J, Zenner H P, Sziklai I, Blin N, Pfister M. Mutation A1555G in the 12S rRNA gene and its epidemiological importance in German, Hungarian, and Polish people. Hum Mutat. 2002; 19 308-309
- 39 Vago P, Humbert G, Lenoir M. Amikacin intoxication induces apoptosis and cell proliferation in rat organ of Corti. Neuroreport. 1998; 9 431-436
- 40 Li L, Nevill G, Forge A. Two modes of hair cell loss from the vestibular sensory epithelia of the guinea pig inner ear. J Comp Neurol. 1995; 355 405-417
- 41 Forge A, Li L. Apoptotic death of hair cells in mammalian vestibular sensory epithelia. Hear Res. 2000; 139 97-115
- 42 Bernardi P, Broekemeier K M, Pfeiffer D R. Recent progress on regulation of the mitochondrial permeability transition pore; a cyclosporin-sensitive pore in the inner mitochondrial membrane. J Bioenerg Biomembr. 1994; 26 509-517
- 43 Pirvola U, Xing-Qun L, Virkkala J, Saarma M, Murakata C, Camoratto A M, Walton K M, Ylikoski J. Rescue of hearing, auditory hair cells and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation. J Neurosci. 2000; 20 43-50
- 44 Bodmer D, Brors D, Bodmer M, Ryan A F. Schutz der Haarzellen vor Gentamicin-vermittelter Ototoxizität durch CEP-11 004, ein Inhibitor der Janus-kinase Signaltransduktionskaskade. Laryngo-Rhino-Otol. 2002; 81 853-856
- 45 Ylikoski J, Xing-Qun L, Virkkala J, Pirvola U. Blockade of c-Jun N-terminal kinase pathway attenuates gentamicin-induced cochlear and vestibular hair cell death. Hear Res. 2002; 163 71-81
- 46 Marchionni M A, Grinspan J B, Canoll P D, Mahanthappa N K, Salzer J L, Scherer S S. Neuregulins as potential neuroprotective agents. Ann NY Acad Sci. 1997; 825 348-365
- 47 Agerman K, Canlon B, Duan M, Ernfors P. Neurotrophins, NMDA receptors, and nitric oxide in development and protection of the auditory system. Ann N Y Acad Sci. 1999; 28 131-142
- 48 Ernfors P, Duan M L, ElShami W M, Canlon B. Protection of auditory neurons from aminoglycoside toxicity by neurotrophin-3. Nat Med. 1996; 2 463-467
- 49 Staeker H, Kopke R, Malgrange B, Lefebvre P, van de Water T R. NT-3 and/or BDNF therapy prevents loss of auditory neurons following loss of hair cells. Neuroreport. 1996; 22 889-894
- 50 Staeker H, Dazert S, Malgrange B, Lefebvre P, Ryan A F, van de Water T R. Transforming growth factor alpha treatment alters intracellular calcium levels in hair cells and protects them from ototoxic damage in vitro. Int J Dev Neurosci. 1997; 15 553-562
- 51 Low W, Dazert S, Baird A, Ryan A F. Basic fibroblast growth factor (FGF-2) protects rat cochlear hair cells in organotypical culture from aminoglycoside injury. J Cell Physiol. 1996; 167 443-450
- 52 Ruan R S, Leong S K, Mark I, Yeoh K H. Effects of BDNF and NT-3 on hair cell survival in guinea pig cochlea damaged by kanamycin treatment. Neuroreport. 1999; 13 2067-2071
- 53 Staeker H, Gabaizadeh R, Federoff H, van de Water T R. Brain-derived neurotrophic factor gene therapy prevents spiral ganglion degeneration after hair cell loss. Otolaryngol Head Neck Surg. 1998; 119 7-13
- 54 Kopke R D, Liu W, Gabaizadeh R, Jacono A, Feghali J, Spray D, Garcia P, Steinman H, Malgrange B, Ruben R J, Rybak L, van de Water T R. Use of organotypic cultures of Corti’s organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory cells. Am J Otol. 1997; 18 559-571
- 55 Ravi R, Somani S M, Rybak L P. Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol. 1995; 76 386-394
- 56 Rybak L P, Husain K, Whitworth C, Somani S M. Dose dependent protection by lipoic acid against cisplatin-induced ototoxicity in rats: antioxidant defense system. Toxicol Sci. 1999; 47 195-202
- 57 Watanabe H, Kanno H. Experimental studies on the protective effect of deferoxamine mesilate on cisplatin induced toxicity. Nippon Jibiinka Gakkai Kaiho. 1998; 101 967-978
- 58 Baliga R, Zhang Z, Baliga M, Ueda N, Shah S V. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int. 1998; 53 394-401
- 59 Li G, Sha S H, Zotova E, Arezzo J, van de Water T, Schacht J. Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action. Lab Invest. 2002; 82 585-596
- 60 Lautermann J, Crann S A, McLaren J, Schacht J. Glutathione-dependent antioxidant systems in the mammalian inner ear: effects of aging, ototoxic drugs and noise. Hear Res. 1997; 114 75-82
- 61 Rybak L P, Ravi R, Somani S M. Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: antioxidant system. Fundam Appl Toxicol. 1995; 26 293-300
- 62 Lautermann J, Song B, McLaren J, Schacht J. Diet is a risk factor in cisplatin ototoxicity. Hear Res. 1995b; 88 47-53
- 63 Dewys W D, Begg C, Lavin P T, Band P R. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med. 1980; 69 491-497
- 64 Nuutinen L S, Kauppila A, Ryhänen P, Niinimäki A, Kivinen S, Saarela M, Pakarinen A, Hollmen A. Intensified nutrition as an adjunct to cytotoxic chemotherapy in gynaecologic cancer patients. Clin Oncol. 1982; 8 107-112
- 65 Blakley B W, Gupta A K, Myers S F, Schwan S. Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg. 1994; 120 541-546
- 66 Campbell K C, Rybak L P, Meech R P, Hughes L. D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res. 1996; 102 90-98
- 67 Kaltenbach J A, Church M W, Blakley B W, McCaslin D L, Burgio D L. Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster. Otolaryngol Head Neck Surg. 1997; 117 493-500
- 68 Doolittle N D, Muldoon L L, Brummett R E, Tyson R M, Lacy C, Bubalo J S, Kraemer D F, Heinrich M C, Henry J A, Neuwelt E A. Delayed sodium thiosulfat as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res. 2001; 7 493-500
- 69 Blakley B W, Cohen J I, Doolittle N D, Muldoon L L, Campbell K C, Dickey T T, Neuwelt E A. Strategies for prevention of toxicity caused by platinum-based chemotherapy: review and summary of the annual meeting of the blood-brain barrier disruption program, Gleneden Beach, Oregon, March 10, 2001. Laryngoscope. 2002; 11 997-2001
- 70 Eckborn A, Laurell G, Johnstrom P, Wallin I, Eksborg S, Ehrsson H. D-Methionin and cisplatin ototoxicity in the guinea pig: D-methionine influences cisplatin pharmcokinetics. Hear Res. 2002; 165 53-61
- 71 Korver K D, Rybak L P, Whitworth C, Campbell K M. Round window application of D-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg. 2002; 126 683-689
- 72 Li G, Frenz D A, Brahmblatt S, Feghali J G, Ruben R J, Berggren D, Arezzo J, van de Water T R. Round window membrane delivery of L-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy. NeuroToxicology. 2001; 22 163-176
- 73 Watanabe K, Inai S, Jinnouchi K, Bada S, Hess A, Michel O, Yagi T. Nuclear-factor kappa B (NF-kappa B)-inducible nitric oxide synthase (iNOS/NOS II) pathway damages the stria vascularis in cisplatin-treated mice. Anticancer Res. 2002; 22 4081-4085
- 74 Cardinaal R M, de Groot J C, Huizing E H, Veldman J E, Smoorenburg G F. Dose-dependent effect of 8-day cisplatin administration upon the morphology of the albino guinea pig cochlea. Hear Res. 2000; 144 135-146
- 75 Watanabe K, Hess A, Bloch W, Michel O. Nitric oxide synthase inhibitor suppresses the ototoxic side effect of cisplatin in guinea pigs. Anticancer drugs. 2000; 11 401-406
- 76 Nicotera P, Leist M, Ferrando-May E. Apoptosis and necrosis: different execution of the same death. Biochem Soc Symp. 1999; 66 69-73
- 77 Watanabe K, Jinnouchi K, Yagi T. Detection of single-stranded DNA (ssDNA) in the vestibule of guinea pigs after the application of cisplatinum (CDDP). Anticancer Res. 2001; 21 1135-1138
- 78 Liu W, Staecker H, Stupak H, Malgrange B, Levebre P, van de Water T R. Caspase inhibitors prevent cisplatin-induced apoptosis of auditory sensory cells. Neuroreport. 1998; 9 2609-2614
- 79 Zheng J L, Gao W Q. Differential damage to auditory neurons and hair cells by ototoxins and neuroprotection by specific neurotrophins in rat organotypic cultures. Eur J Neurosci. 1996; 8 1897-1905
- 80 Browers W J, Chen X, Guo H, Frisina D R, Federoff H J, Frisina R D. Neurotrophin-3 transduction attenuates cisplatin spiral ganglion neuron ototoxicity in the cochlea. Mol Ther. 2002; 6 12-18
Priv.-Doz. Dr. Jürgen Lautermann
St. Elisabeth Hospital · HNO-Klinik
Bleichstraße 15 · 44787 Bochum
Email: j.lautermann@klinikum-bochum.de